Stifel analyst Jonathan Block upgraded Idexx Laboratories (IDXX) to Buy from Hold with a price target of $700, up from $640. The firm expects the company’s CAG – Companion Animal Group – recurring revenue growth to accelerate over the next couple of years as price realization steps down modestly, while visits and the “premium” improves, the analyst tells investors in a research note. Idexx visits are stronger than the current trends suggest, and Cancer Dx can aid the premium as the tests’ utility expands, the firm added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories’ Innovative Diagnostics Drive Buy Rating Amid Strong Growth Prospects
- IDEXX Laboratories Appoints Karen Peacock to Board
- Apple initiated, DraftKings downgraded: Wall Street’s top analyst calls
- Idexx Laboratories initiated with a Neutral at UBS
- Idexx Laboratories: Balancing Growth Opportunities and Revenue Challenges in a High-Growth Sector